Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryFeb042010	Fate Therapeutics Receives Allowance of First U.S. Patent for Induced Pluripotent Stem Cell Technology San Diego, CA – Fate Therapeutics, Inc. received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application Number 10/997,146 entitled “Methods for Reprogramming Somatic Cells.” Upon issuance, the patent will cover foundational induced Read All »	View HTML Fate Therapeutics Receives Allowance of First U.S. Patent for Induced Pluripotent Stem Cell Technology 12.6 KB
Toggle SummarySep262016	Fate Therapeutics Receives FDA Orphan Drug Designation for ProTmune™ in Allogeneic Hematopoietic Cell Transplantation SAN DIEGO, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Read All »	View HTML Fate Therapeutics Receives FDA Orphan Drug Designation for ProTmune™ in Allogeneic Hematopoietic Cell Transplantation 16 KB
Toggle SummaryJun282010	Fate Therapeutics Receives Red Herring's North America 100 Award for Advancing Stem Cell Technology and New Medicines San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announced today that the Company received Red Herring’s North America 100 award, a prestigious list honoring the year’s most promising private and innovative companies from the North American business region. Read All »	View HTML Fate Therapeutics Receives Red Herring’s North America 100 Award for Advancing Stem Cell Technology and New Medicines 189.8 KB
Toggle SummaryMay132014	Fate Therapeutics Reports First Quarter 2014 Financial Results Phase 2 PUMA Study of PROHEMA® in Adult Hematologic Malignancies Enrolling Patients Phase 1b PROMPT Study of PROHEMA in Pediatric Hematologic Malignancies Cleared by FDA IND Submission for Study of PROHEMA in Rare Genetic Disorders Expected in 2Q14 SAN DIEGO, May 13, 2014 (GLOBE NEWSWIRE) -- Read All »	View HTML Fate Therapeutics Reports First Quarter 2014 Financial Results 25.2 KB
Toggle SummaryMay072015	Fate Therapeutics Reports First Quarter 2015 Financial Results Strategic Research Collaboration Established with Juno Therapeutics to Apply Small Molecule Modulators for Programming CAR and TCR Immunotherapies Additional Data from Ongoing Phase 2 PUMA Study of PROHEMA® Continue to Demonstrate Acceleration of, and Increased Incidence of Early, Neutrophil Read All »	View HTML Fate Therapeutics Reports First Quarter 2015 Financial Results 30.9 KB
Toggle SummaryMay092016	Fate Therapeutics Reports First Quarter 2016 Financial Results Phase 1/2 Clinical Trial of ProTmune™ for Prevention of Acute GvHD and CMV Infection to Begin Enrollment in mid-2016 Adaptive NK Cell Cancer Immunotherapy to be Featured at Innate Killer Summit in mid-May Immuno-Regulatory CD34 + Cell Therapy Abstract Accepted for Presentation at American Read All »	View HTML Fate Therapeutics Reports First Quarter 2016 Financial Results 34.2 KB
Toggle SummaryMay152017	Fate Therapeutics Reports First Quarter 2017 Financial Results ProTmune™ PROTECT Safety Data Expected in Mid-2017 Launched First-in-Human Clinical Trial of FATE-NK100 for Acute Myelogenous Leukemia IND Cleared by FDA for FATE-NK100 with Monoclonal Antibody Therapy in Advanced Solid Tumors Conducted Formal Regulatory Meetings with FDA and MHRA for Engineered Read All »	View HTML Fate Therapeutics Reports First Quarter 2017 Financial Results 34.1 KB
Toggle SummaryMay102018	Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress No Cancer Relapse Reported in Phase 1 PROTECT Study of ProTmune Anti-tumor Activity with No Dose-limiting Toxicities Observed in Initial Phase 1 Dose Escalation of FATE-NK100 in Advanced Solid and Liquid Tumors IND for Off-the-Shelf NK Cell Product FT500 Remains on Track for 2Q18 Submission Read All »	View HTML
Toggle SummaryMay072019	Fate Therapeutics Reports First Quarter 2019 Financial Results and Highlights Operational Progress First-ever Patient Treated in U.S. with an iPSC-derived Cell Therapy Successfully Advances through Six-dose Treatment Course No Dose-Limiting Toxicities or Serious Adverse Events Reported in Initial Cohort of FT500 iPSC-derived NK Cell Cancer Immunotherapy Patients FT500 Clinical Trial Now Open for Read All »	View HTML
Toggle SummaryMay112020	Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress Worldwide Collaboration Formed with Janssen for Novel iPSC-derived CAR NK and CAR T-Cell Product Candidates First Patient Treated with FT596, the First-ever Cellular Immunotherapy Engineered with Three Active Anti-tumor Modalities Second FT596 IND Allowed by FDA for Relapse Prevention after Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.